Needham & Company LLC Boosts OncoCyte (NASDAQ:OCX) Price Target to $4.25

OncoCyte (NASDAQ:OCX) had its price objective boosted by Needham & Company LLC from $3.60 to $4.25 in a report released on Wednesday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts also recently commented on the stock. StockNews.com assumed coverage on shares of OncoCyte in a research note on Wednesday. They set a sell rating for the company. Benchmark reiterated a speculative buy rating and set a $5.00 target price on shares of OncoCyte in a research note on Monday, April 15th. Finally, Stephens reiterated an equal weight rating and set a $4.00 target price on shares of OncoCyte in a research note on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of Hold and an average target price of $4.06.

OncoCyte Stock Up 1.6 %

OncoCyte stock opened at $2.48 on Wednesday. OncoCyte has a twelve month low of $2.08 and a twelve month high of $6.20. The stock’s fifty day simple moving average is $2.89 and its 200-day simple moving average is $3.03.

Insider Buying and Selling at OncoCyte

In related news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the firm’s stock in a transaction on Thursday, April 11th. The stock was bought at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the completion of the purchase, the insider now directly owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, major shareholder Broadwood Partners, L.P. acquired 2,420,000 shares of the firm’s stock in a transaction on Thursday, April 11th. The stock was bought at an average price of $2.92 per share, for a total transaction of $7,066,400.00. Following the completion of the purchase, the insider now directly owns 4,929,066 shares of the company’s stock, valued at approximately $14,392,872.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Andrew Arno acquired 33,898 shares of the firm’s stock in a transaction on Thursday, April 11th. The stock was bought at an average price of $2.95 per share, with a total value of $99,999.10. Following the purchase, the director now directly owns 69,054 shares of the company’s stock, valued at $203,709.30. The disclosure for this purchase can be found here. Insiders purchased 2,457,288 shares of company stock worth $7,176,400 over the last 90 days. Corporate insiders own 1.94% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.